Physician profile
Michael J Wilson
NPI 1972617793
$16,547.83
in general payments reported to CMS, 2019-2025
42 companies · $2,012 in 2025
The $2,012 reported for 2025 was more than what 84% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,283 · 2020: $1,750 · 2021: $3,212 · 2022: $2,801 · 2023: $1,822 · 2024: $1,669 · 2025: $2,012.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,502.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,502.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,938.05 | 2021-2025 | Ffrangio, Micra, Cobalt Dr Mri Surescan |
| Medtronic Vascular, INC. | $2,340.48 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $2,108.82 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $1,707.49 | 2019-2024 | Xarelto |
| Cvrx, INC. | $978.99 | 2024-2025 | Barostim Neo System |
| Astrazeneca Pharmaceuticals LP | $808.55 | 2019-2025 | Farxiga, Brilinta |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $629.95 | 2019-2025 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $605.21 | 2019-2025 | Camzyos, Eliquis |
| Abbott Laboratories | $587.38 | 2019-2023 | Pressurewire |
| Merck Sharp & Dohme LLC | $426.19 | 2021-2025 | Verquvo |
| Penumbra, INC. | $421.05 | 2020-2022 | |
| Boston Scientific Corporation | $371.93 | 2022-2025 | Watchman Flx, Bodyguardian, Watchman Access System |
| Amgen INC. | $361.26 | 2019-2025 | Repatha, Repatha |
| Actelion Pharmaceuticals US, INC. | $340.38 | 2019-2024 | Uptravi, Opsumit |
| Pfizer INC. | $318.41 | 2019-2022 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $164.22 | 2021-2025 | |
| Esperion Therapeutics, INC. | $141.21 | 2021-2024 | Nexletol |
| Alnylam Pharmaceuticals INC. | $137.25 | 2020-2025 | Onpattro |
| Cardiva Medical, INC. | $132.69 | 2022-2023 | Cardiva Vascade 6/7f Vcs |
| Irhythm Technologies, INC. | $128.38 | 2019-2023 | Zio Xt Patch |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.98 | 2023-2025 | Jardiance |
| Abiomed | $78.07 | 2025 | |
| Amarin Pharma, INC. | $54.75 | 2020-2021 | |
| Abbvie INC. | $52.96 | 2024 | |
| Sanofi-Aventis U.S. LLC | $51.05 | 2019-2023 | |
| Lexicon Pharmaceuticals, INC. | $49.48 | 2024 | |
| Lilly USA, LLC | $42.05 | 2024 | Mounjaro, Zepbound |
| Biotronik INC. | $41.90 | 2019 | |
| Tactile Systems Technology INC | $40.84 | 2020-2021 | |
| Impulse Dynamics (USA) INC. | $39.78 | 2024-2025 | Optimizer |
| Imperative Care, INC | $38.89 | 2025 | Symphony Catheter |
| Braemar Manufacturing, LLC | $37.09 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $35.20 | 2024 | Arcalyst |
| Atricure, INC. | $33.84 | 2025 | Epi-Sense Guided Coagulation System With Visitrax |
| Lundbeck LLC | $32.21 | 2019-2021 | |
| Novo Nordisk INC | $27.24 | 2023-2024 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $23.57 | 2025 | Arexvy, Shingrix |
| Acera Surgical, INC. | $21.07 | 2024 | Restrata Wound Matrix |
| Zoll Circulation INC | $18.72 | 2021 | |
| Janssen Scientific Affairs, LLC | $18.70 | 2021 | |
| Kiniksa Pharmaceuticals, LTD. | $17.80 | 2023 | Arcalyst |
| Chiesi USA, INC. | $17.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.